Synta Skin Cancer Drug Granted Fast Track
Posted on: Wednesday, 15 November 2006, 15:00 CST
Synta Pharmaceuticals has said its oncology drug candidate, STA-4783, has been granted fast track designation by the FDA for the treatment of metastatic melanoma, a serious type of skin cancer.
In a recently completed, phase IIb trial in patients with metastatic malignant melanoma, treatment with STA-4783 plus paclitaxel achieved the primary endpoint of increasing progression-free survival.
"Metastatic melanoma is a disease with very limited treatment options for patients and a high mortality rate," said Safi Bahcall, president and CEO of Synta.
The FDA's fast track program is designed to facilitate the development and expedite the review of new drug candidates that are intended to treat serious or life-threatening diseases and that demonstrate the potential to address unmet medical needs.
Fast track designation has no impact on the standard of review or on whether the FDA ultimately approves the drug for marketing.
Source: Datamonitor
Related Articles
- TransMolecular Reports Positive Results From Phase 1 Trial of (131)Iodine-TM601 in Metastatic Melanoma
- Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma
- US FDA Fast Tracks PI-88 for the Treatment of Post Resection Liver Cancer
- Advanced Life Sciences Metastatic Melanoma Drug Granted Orphan Status
- Provectus Receives Orphan Drug Designation From FDA for Anti-Cancer Agent PV-10 for the Treatment Of Metastatic Melanoma
- Medarex Announces Enrollment Complete in Ipilimumab (MDX-010) Monotherapy Pivotal Registrational Trial for Metastatic Melanoma
- AVAX Technologies Launches Global Phase III Registration Clinical Trial of M-Vax in Metastatic Melanoma
- Antigenics Announces Preliminary Survival Data From Its Randomized Phase 3 Metastatic Melanoma Trial
- Metastatic Melanoma Treatment Results Using Inovio's Selective Electrochemical Tumor Ablation Therapy Published in Melanoma Research
- FDA Approves New Lung Cancer Drug
 |
 |
User Comments (0)
RSS Feeds